FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20230919E00149
1. Date of relevant event: 05/09/2023
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 01541
4. Name of listed corporation: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. - B - H Shares 
5. Class of shares: Others 
6. Number of issued shares in class: 145,607,656
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) Yu
(Other names) Zhihua
10. Name of director (Chinese): 余治華 
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1701Miscellaneous
On listing of the corporation or a class of shares of the listed corporation
 
 
2201Interest of corporation controlled by you
 
19,263,240         
 
Short position 
 
 
 
           
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
   
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position19,263,24013.23
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2201Interest of corporation controlled by you
Long position19,263,240
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
           
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
 
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
Beijing Lapam Capital Management Consultant Center (General Partnership) (北京龍磐投資管理諮詢中心(普通合夥))10B1-B3,Tower3,1#Xizhimen Wai Street,Xicheng District,Beijing(PRC)Yu Zhihua100.00N
Long position19,263,240
Tibet Lapam Yijing Venture Capital Center (Limited Partnership) (西藏龍磐怡景創業投資中心(有限合夥))拉薩經濟技術開發區總部壹號公館6幢7層701號(中國)Beijing Lapam Capital Management Consultant Center (General Partnership) (北京龍磐投資管理諮詢中心(普通合夥))100.00N
Long position19,263,240
Beijing Lapam Healthcare Investment Centre (Limited Partnership) (北京龍磐健康醫療投資中心(有限合夥))北京市海澱區翠微路12號5層1單元501-7(中國)Tibet Lapam Yijing Venture Capital Center (Limited Partnership) (西藏龍磐怡景創業投資中心(有限合夥))100.00Y
Long position19,263,240
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
  
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: Box 5: It refers to the class of unlisted shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
35. Log/Serial Number of the previous form:
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 19/09/2023
(dd/mm/yyyy)